Aussie invention could lower risk of repeat MI

The CSL formulation of apolipoprotein A-I (the active component of high-density lipoprotein) has been trialled in patients with stable cardiovascular disease.

Results of the phase IIa trial of the formulation, CSL112, were presented to the American Heart Association’s Scientific Sessions 2013 in Dallas today.

CSL112 is purified from human plasma and reconstituted to form HDL particles suitable for intravenous infusion.

The data showed a dramatic and rapid increase in key indicators of reverse cholesterol transport, a process by which cholesterol is rapidly removed from arteries and transported to the